prod:prod_dcx-login
Xpert® TV
The First MolecularTrichomonas VaginalisTest for Both Women and Men
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXTV-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
ASWAB Dual Swab Specimen Collection Kit (Pack of 50)
SWAB/A-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Urine Collection Kit (Pack of 50)
URINE/A-50
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Identification of Trichomonas vaginalis (TV) infections is problematic. The demanding nature of this fragile organism outside its ideal living conditions, compounded with the poor sensitivity of wet mount microscopy and time delays for conclusive diagnosis from culture methods, makes detection of this asymptomatic infection a challenge. Symptoms alone are insufficient to diagnose a TV infection. In women, the characteristics of vaginal discharge, color and odor, are poor predictors of this commonly asymptomatic infection.1 TV was found in over 73% of the male partners of women with trichomoniasis.2
To prevent serial reinfection, all recent and current sex partners of patients with acute, persistent, or recurrent trichomoniasis should be treated or referred for treatment regardless of symptoms.3
What would help laboratories offering TV testing?
To prevent serial reinfection, all recent and current sex partners of patients with acute, persistent, or recurrent trichomoniasis should be treated or referred for treatment regardless of symptoms.3
What would help laboratories offering TV testing?
- Accurate, reliable, and reproducible tests
- Test indications for male and female specimens
- Elimination of repetitive microscopy readings
- Less time preparing samples and reagents
(1) Centers for Disease Control and Prevention. Trichomoniasis —CDC Fact Sheet. Accessed Aug 2021. https://www.cdc.gov/std/trichomonas/stdfact-trichomoniasis.htm
(2) Van Gerwen O, et al. Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. Clin Infect Dis. 2021 Jun 3; ciab514.
(3) Workowski KA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70 (No. RR-4):1–187.
* Early Assay Termination for positive results.
(2) Van Gerwen O, et al. Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men. Clin Infect Dis. 2021 Jun 3; ciab514.
(3) Workowski KA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70 (No. RR-4):1–187.
* Early Assay Termination for positive results.
The Solution
Now anyone can run a TV test with confidence. Each test cartridge contains everything you need, including three controls to ensure test integrity and performance. With Xpert TV, same-day patient consultation and treatment are now a reality for clinicians.
On-demand TV testing — a next generation solution:
On-demand TV testing — a next generation solution:
- The first NAAT to deliver TV results for male urine samples
- Near patient easy-to-use technology
- Intended for both symptomatic and asymptomatic patients so clinicians can screen individuals at higher risk of infection
- Sample Adequacy Control (SAC) — confirms adequate patient sample collection
- Sample Processing Control (SPC) — ensures the sample is correctly processed
- Probe Check Control (PCC) — monitors reagent systems in each and every cartridge
The Impact
Nucleic acid amplification tests (NAATs) offer the highest sensitivity for the detection of TV. Improve your laboratory workflow with simple, on-demand, random-access flexibility. Combine performance with the ability to run other tests (such as SARS-CoV-2, CT/NG, MG, HPV, HIV, HCV, and GBS) on the GeneXpert® System to improve overall service levels of your laboratory.
Shift from reactive to proactive
Shift from reactive to proactive
- Deliver high sensitivity NAAT results for accurate diagnosis in both men and women
- Deliver near patient results on-demand as soon as 40* – 65 minutes
- Support patient consultations with real time results
- Help patients and their partners live healthier lives
Related Products
Xpert HPV
Reliable Detection of High-Risk HPV DNA with Genotyping of HPV 16 and 18/45
Xpert CT/NG
90-minute detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG)
Product Resources
Product Information
Package Inserts & MSDS
Frequently Asked Questions
Xpert TV is a qualitative in vitro diagnostic test for the detection of Trichomonas vaginalis genomic DNA. The test utilizes automated real-time PCR to amplify and detect Trichomonas vaginalis genomic DNA. (1)
The Xpert TV test uses female and male urine specimens, endocervical swab specimens, or patient-collected vaginal swab specimens (collected in a clinical setting). The Xpert TV test is intended to aid in the diagnosis of trichomoniasis (TV) in symptomatic or asymptomatic individuals. (1)
The protozoan Trichomonas vaginalis is responsible for trichomoniasis, which is a common sexually transmitted infection that can infect both men and women. There are 7.4 million cases of trichomoniasis annually in the United States. Trichomoniasis can be symptomatic or asymptomatic. (1)
In women, trichomoniasis is one of a range of conditions that may include vaginal discharge. Symptoms in females can include itching, burning, redness, or soreness of the genitals, unusual odor, discomfort with urination, or a thin clear, white, yellow, or green discharge. (2) In men, trichomoniasis may cause non-gonococcal urethritis (NGU). Symptoms in males can include itching or burning inside the penis, burning after ejaculation or urination, or penile discharge. (1)
For women, consider screening those receiving care in high-prevalence settings (e.g., STI clinics and correctional facilities) and for asymptomatic women at high risk for infection (e.g., women with multiple sex partners, transactional sex, drug misuse, or a history of STI or incarceration). For persons with HIV, screening is recommended for sexually active women at entry to care and at least annually thereafter. (2)
References:
- Cepheid. Xpert TV Package Insert. Accessed Dec. 18, 2023. https://www.cepheid.com/en-ILntent/dam/www-cepheid-com/documents/package-insert-files/Xpert-TV-ENGLISH-Package-Insert-301-2887-Rev.%20D.pdf
- CDC. Screening Recommendations and Considerations Referenced in Treatment Guidelines and Original Sources. June 6, 2022. Accessed Dec. 18, 2023. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm